Current landscape of immunotherapy for CNS tumors.
作者信息
Landry Alexander P, Dunn Gavin P, Lim Michael
机构信息
Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv1-iv3. doi: 10.1093/noajnl/vdaf118. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
Current landscape of immunotherapy for CNS tumors.中枢神经系统肿瘤免疫治疗的现状
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv1-iv3. doi: 10.1093/noajnl/vdaf118. eCollection 2025 Sep.
2
Overcoming the blood-brain barrier (BBB) in pediatric CNS tumors: immunotherapy and nanomedicine-driven strategies.克服小儿中枢神经系统肿瘤中的血脑屏障：免疫疗法和纳米医学驱动策略
Med Oncol. 2025 Aug 19;42(10):431. doi: 10.1007/s12032-025-02984-y.
3
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion.为具有可操作改变的非小细胞肺癌患者在整个治疗过程中推动最佳实践：播客讨论
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03195-7.
4
CAR T cell therapy for central nervous system solid tumors: current progress and future directions.中枢神经系统实体瘤的嵌合抗原受体T细胞疗法：当前进展与未来方向
Front Immunol. 2025 Aug 15;16:1600403. doi: 10.3389/fimmu.2025.1600403. eCollection 2025.
5
Immunotherapy in central nervous system tumour.中枢神经系统肿瘤的免疫疗法
Int J Surg. 2025 Jul 23. doi: 10.1097/JS9.0000000000002993.
6
Molecular genomic landscape of pediatric solid tumors in Chinese patients: implications for clinical significance.中国儿童实体瘤的分子基因组图谱：对临床意义的启示。
J Cancer Res Clin Oncol. 2023 Sep;149(11):8791-8802. doi: 10.1007/s00432-023-04756-5. Epub 2023 May 4.
7
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.世界卫生组织中枢神经系统肿瘤分类的分子检测：综述
JAMA Oncol. 2025 Mar 1;11(3):317-328. doi: 10.1001/jamaoncol.2024.5506.
8
Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists.中枢神经系统间充质非脑膜瘤：不断演变的分子格局及其对神经放射科医生的意义
AJNR Am J Neuroradiol. 2025 May 2;46(5):868-878. doi: 10.3174/ajnr.A8519.
9
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.《嗜铬细胞瘤和副神经节瘤的免疫景观：当前进展与展望》
Endocr Rev. 2024 Jul 12;45(4):521-552. doi: 10.1210/endrev/bnae005.
10
Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.美国医院中原发性中枢神经系统肿瘤分子检测的可及性和使用情况。
J Neuropathol Exp Neurol. 2024 Jun 20;83(7):579-585. doi: 10.1093/jnen/nlae035.
本文引用的文献
1
Intravenous and intracranial GD2-CAR T cells for H3K27M diffuse midline gliomas.用于H3K27M弥漫性中线胶质瘤的静脉内和颅内GD2嵌合抗原受体T细胞
Nature. 2025 Jan;637(8046):708-715. doi: 10.1038/s41586-024-08171-9. Epub 2024 Nov 13.
2
Viruses in glioblastoma: an update on evidence and clinical trials.胶质母细胞瘤中的病毒：证据与临床试验的最新进展
BJC Rep. 2024 Apr 19;2(1):33. doi: 10.1038/s44276-024-00051-z.
3
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.胶质母细胞瘤的免疫治疗：现状、挑战与未来展望。
Cell Mol Immunol. 2024 Dec;21(12):1354-1375. doi: 10.1038/s41423-024-01226-x. Epub 2024 Oct 15.
4
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌的总生存期。
N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15.
5
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.免疫检查点抑制剂与胶质母细胞瘤：当前状况及未来方向综述
J Immunother Precis Oncol. 2024 May 2;7(2):97-110. doi: 10.36401/JIPO-23-34. eCollection 2024 May.
6
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.了解胶质瘤的免疫抑制微环境：机制见解和临床观点。
J Hematol Oncol. 2024 May 8;17(1):31. doi: 10.1186/s13045-024-01544-7.
7
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.靶向复发性胶质母细胞瘤中表皮生长因子受体（EGFR）和白细胞介素13受体α2（IL13Rα2）的鞘内双特异性嵌合抗原受体（CAR）T细胞：1期试验中期结果
Nat Med. 2024 May;30(5):1320-1329. doi: 10.1038/s41591-024-02893-z. Epub 2024 Mar 13.
8
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.脑室 CARv3-TEAM-E 细胞治疗复发性脑胶质瘤。
N Engl J Med. 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13.
9
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.帕博利珠单抗联合曲妥珠单抗和化疗治疗 HER2 阳性胃或胃食管交界腺癌：来自 3 期 KEYNOTE-811 随机安慰剂对照试验的中期分析。
Lancet. 2023 Dec 9;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0. Epub 2023 Oct 20.
10
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.临床试验将溶瘤免疫激活与胶质母细胞瘤的生存联系起来。
Nature. 2023 Nov;623(7985):157-166. doi: 10.1038/s41586-023-06623-2. Epub 2023 Oct 18.
Zotero 插件